GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Organovo Holdings Inc (NAS:ONVO) » Definitions » Cash Flow from Investing

Organovo Holdings (Organovo Holdings) Cash Flow from Investing : $0.64 Mil (TTM As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Organovo Holdings Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Dec. 2023, Organovo Holdings spent $0.00 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $1.97 Mil on purchasing investments. It gained $2.72 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.72 Mil for other investing activities. In all, Organovo Holdings gained $0.03 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Dec. 2023.


Organovo Holdings Cash Flow from Investing Historical Data

The historical data trend for Organovo Holdings's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Organovo Holdings Cash Flow from Investing Chart

Organovo Holdings Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.08 0.75 -0.39 -0.41 -0.97

Organovo Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.98 -0.16 0.76 0.01 0.03

Organovo Holdings Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Organovo Holdings's Cash Flow from Investing for the fiscal year that ended in Mar. 2023 is calculated as:

Organovo Holdings's Cash Flow from Investing for the quarter that ended in Dec. 2023 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.64 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Organovo Holdings  (NAS:ONVO) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Organovo Holdings's purchase of property, plant, equipment for the three months ended in Dec. 2023 was $0.00 Mil. It means Organovo Holdings spent $0.00 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Organovo Holdings's sale of property, plant, equipment for the three months ended in Dec. 2023 was $0.00 Mil. It means Organovo Holdings gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Organovo Holdings's purchase of business for the three months ended in Dec. 2023 was $0.00 Mil. It means Organovo Holdings spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Organovo Holdings's sale of business for the three months ended in Dec. 2023 was $0.00 Mil. It means Organovo Holdings gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Organovo Holdings's purchase of investment for the three months ended in Dec. 2023 was $-1.97 Mil. It means Organovo Holdings spent {stock_data.stock.currency_symbol}}1.97 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Organovo Holdings's sale of investment for the three months ended in Dec. 2023 was $2.72 Mil. It means Organovo Holdings gained $2.72 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Organovo Holdings's net Intangibles purchase and sale for the three months ended in Dec. 2023 was $0.00 Mil. It means Organovo Holdings paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Organovo Holdings's cash from discontinued investing activities for the three months ended in Dec. 2023 was 0.00 Mil. It means Organovo Holdings paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Organovo Holdings's cash from other investing activities for the three months ended in Dec. 2023 was $-0.72 Mil. It means Organovo Holdings paid $0.72 Mil for other investing activities.


Organovo Holdings Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Organovo Holdings's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Organovo Holdings (Organovo Holdings) Business Description

Traded in Other Exchanges
Address
11555 Sorrento Valley road, Suite 100, San Diego, CA, USA, 92121
Organovo Holdings Inc is a biotechnology company, which designs and creates functional and three-dimensional human tissues for medical research and therapeutic applications. It also develops and commercializes a platform technology for the generation of three-dimensional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The company collaborates with pharmaceutical and academic partners to develop human biological disease models in three dimensions. Organovo's key instrument platform is the NovoGen Bioprinter. The firm's 3-D bioprinting technologies create tissues using living cells and biocompatible hydrogels.
Executives
David Gobel director 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Vaidehi Joshi director C/O ORGANOVO HOLDINGS, INC., 11555 SORRENTO VALLEY ROAD, SUITE 100, SAN DIEGO CA 92121
Alison Tjosvold Milhous director 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Adam K Stern director STERN AEGIS VENTURES, 810 7TH AVENUE 22ND FLOOR, NEW YORK NY 10019
Thomas Hess officer: President, CFO and PFO 366 MADISON AVE. 12TH FLOOR, NEW YORK NY 10017
Douglas Jay Cohen director 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Thomas E Jurgensen officer: General Counsel & Secretary 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Jeffrey N. Miner officer: Chief Scientific Officer 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Chris Heberlig officer: President and CFO C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Keith Murphy director, officer: Executive Chairman 6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
Steven George Hughes officer: Chief Medical Officer 6275 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Carolyn Beaver director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
David Shapiro director C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES ST., NEW YORK NY 10013
Presnell Sharon Collins officer: EVP, Research & Development 6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
Taylor Crouch director, officer: CEO & President 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075

Organovo Holdings (Organovo Holdings) Headlines

From GuruFocus

Organovo Achieves 3D Tissue Model for Crohn's Disease

By GuruFocusNews GuruFocusNews 05-27-2022

Catherine Wood's ARK Investment Slashes Organovo Holding

By Graham Griffin Graham Griffin 03-11-2021

Organovo Achieves 3D Tissue Model for Crohn's Disease

By GuruFocusNews GuruFocusNews 06-06-2022

Organovo Achieves 3D Tissue Model for Crohn's Disease

By GuruFocusNews GuruFocusNews 07-06-2022